​​Innovative therapies
                         Superior outcomes

Trevor Sweatman, PhD

Director of Clinical Pharmacology

Dr. Soberman, Chief Medical Officer, is a Professor of Cardiovascular Disease at the Univ. of Tennessee Health Science Center with over 35 years of clinical and research experience in cardiac arrhythmias, heart failure and device implantation. She has been a Principal Investigator or Co-Investigator on multiple pharmacological clinical trials, as well as serving as Primary Cardiovascular Consultant on numerous multicenter NIH and industry-sponsored clinical trials.  Dr. Soberman is a Certified Cardiac Device Specialist and a Fellow in both the Heart Rhythm Society and the American College of Cardiology.  She has been a funded researcher in preventative cardiology studies including NIDDK-sponsored trials of diabetes management and the Women's Health Initiative.  She has been awarded independent funding for her work in antitumor drug cardiotoxicity/cardioprotection.  Dr. Soberman earned her Sc.B. in Molecular Biology from Brown Univ. and her MD from the Univ. of Pittsburgh.  She completed her residency training in Internal Medicine at the Albert Einstein College of Medicine (AECOM) in NY, fellowship training in Cardiovascular Pharmacology at the Belfer Institute for Advanced Biomedical Research (NY) and fellowship training in Cardiovascular Disease and Pacemaker/Arrhythmia at the Montefiore Medical Center of AECOM.  Dr. Soberman also holds a Masters in Healthcare Administration from the Univ. of Memphis, where she holds an adjunct faculty appointment in Biomedical Engineering.

Dr. Sweatman is a Professor of Pharmacology at the University of Tennessee Health Science Center with over 30 years of experience in qualitative and quantitative drug analysis of clinical samples, pharmacokinetics and cancer drug development.  Dr. Sweatman has an extensive track record of publication and NIH funding in the development, mechanistic analyses and preclinical and clinical testing of novel anthracycline compounds, including Valstar®, an FDA-approved agent for the treatment of bladder cancer.  He is a member of the UT Center for Cancer Research, and has formerly been an Associate Editor of Clinical Cancer Research, Representative to the United States Pharmacopeia Convention, and Consultant in Pharmacology, Huntington Medical Research Institute (Pasadena, CA).  Dr. Sweatman earned a B.Sc (Honors) in Applied Biology from Hatfield Polytechnic (UK) and his Ph.D. with the Clinical Pharmacology group from Southampton University Medical School (UK), followed by post-doctoral training in Pharmacology at the Dana-Farber Cancer Institute.

Dr. Rimoldi brings considerable drug synthesis experience to the mission of Paradox Pharmaceuticals.  He is currently Professor of Medicinal Chemistry in the Dept. of Biomolecular Sciences and Research Professor of the Research Institute of Pharmaceutical Sciences at the Univ. of Mississippi School of Pharmacy.  He has published over 65 papers and holds multiple patents in the areas of synthetic medicinal chemistry, drug design and development, bioorganic chemistry and environmental toxicology.  Dr. Rimoldi currently serves as Assoc. Editor of the Journal of Medicinal Chemistry Letters, is on the editorial board of Perspectives in Medicinal Chemistry, Open Medicinal Chemistry Journal, and The Bulletin of Environmental Contamination and Toxicology.  He has been an active NIH SBIR/STTR grant reviewer since 1998, and serves as a scientific reviewer for the Dept. of Defense Breast Cancer Research Program.  He has received research funding from NIH, CDC, USDA, NOAA, American Heart Assoc. and the American Assoc. of Colleges of Pharmacy.  He is Chair-Elect of the Section of Chemistry in The American Assoc. of Colleges of Pharmacy, Chair of the Ole Miss Section of the American Chemical Society, and President of the MALTO Medicinal Chemistry organization.  Dr. Rimoldi earned his B.S. in Chemistry from the Univ. of Pittsburgh, and his Ph.D. in Chemistry from Virginia Tech, followed by post-doctoral training at the Peters Center for the Study of Parkinson's Disease at Virginia Tech.

John M. Rimoldi, PhD


Leonard Lothstein, PhD

President & CEO

Dr. Israel, a Co-Founder of Paradox Pharmaceuticals and its Chief Scientific Officer, has been a leader in anthracycline drug design and development for over 50 years, with extensive experience in both bench research and drug commercialization.  He was Co-Founder and former Board Chairman of Anthra Pharmaceuticals, Inc.  Dr. Israel was also the discoverer and developer of Valstar®, an FDA-approved agent for the treatment of human bladder cancer, and has extensive experience in FDA regulatory issues and clinical trial conduct.  He holds four U.S. and international patents for novel anthracycline agents.  Dr. Israel's academic experience includes 30 years as Professor of Pharmacology at the University of Tennessee College of Medicine, Professor of Pharmaceutical Sciences at the University of Tennessee College of Pharmacy, member of the UT Center for Anticancer Drug Research and member of the UT Center for Cancer Research, with a long track record of NIH funding resulting in over 350 publications in drug development.  Prior to this, Dr. Israel was a faculty member of the Dana-Farber Cancer Institute/Harvard Medical School holding the position of Associate Chief for Drug Development, Dana-Farber Cancer Institute.  He has been a member of numerous grant review and advisory panels for NIH.

Dr. Lothstein, a Co-Founder, has been President and CEO of Paradox Pharmaceuticals since its founding in 2010.  He is also a tenured faculty member at the University of Tennessee Health Science Center in the Depts. of Pathology and Pharmaceutical Sciences, was a founder of the UT Center for Anticancer Drug Research, was the Director of the Experimental Therapeutics at the UT Center for Cancer Research and is currently a Full Member of the UT/West Cancer Center.  He has 35 years of funded and published research experience and accomplishments in the areas of anticancer drug development, anthracycline pharmacology, anticancer drug resistance and cancer cell signaling, which has been supported by the National Institutes of Health, The American Cancer Society, the Susan G. Komen Foundation, the Pharmaceutical Manufacturers Association Foundation, and the Milheim Foundation for Cancer Research.   Dr. Lothstein has multiple awarded and pending patents on functionally novel anthracycline antitumor agents and targeted drug delivery. He has also served as a Member of numerous NIH grant review and consulting panels.  Dr. Lothstein earned his BA in Biology from Bowdoin College and MS and PhD in Molecular Biology from Vanderbilt University.  He completed his post-doctoral training as a National Cancer Institute-funded Fellow at the Memorial Sloan-Kettering Cancer Center and the Belfer Institute for Advanced Biomedical Studies at the Albert Einstein College of Medicine in New York City.   

Mervyn Israel, PhD

Chief Scientific Officer

Judith E. Soberman, MD, MHA, FACC, FHRS

Chief Medical Officer

Management Team